Call Us: 1.800.873.5297

By

New Lupus Drug may have Passed Key Test

After over 50 years of waiting for a new lupus treatment, researchers may have developed can reduce the symptoms of the life-threatening autoimmune disorder that afflicts as many as 1.5 million Americans.

Lupus is a chronic inflammatory disease in which the body’s immune system attacks its own tissues and organs. About 90% of patients are women, usually in their 30s and 40s when it first strikes. Typical symptoms can include fatigue, fever, joint pain, stiffness and swelling, rashes, skin lesions, mouth sores, hair loss and chest pain. The disease can attack many internal organs, leading eventually to death.

In unpublished results released by the Human Genome Sciences company said that the experimental drug Benlysta significantly reduced lupus symptoms in a randomized trial of 865 patients, reducing their need for steroids and improving quality of life.

The new trial was conducted in 865 patients at 90 sites in 13 countries, primarily abroad. Patients all had active lupus, although none had a severe form requiring hospitalization, and received normal care for the disease. The participants were randomly placed into three groups, two receiving different amounts of the drug and the third receiving a placebo. Patients were given an infusion of the drug at the beginning of the trial, at two weeks, at four weeks, and then every four weeks after that. They were followed for 52 weeks.

About 58% of patients who received the highest dose of Benlysta showed a significant improvement on an index used to assess impact, compared with 46% of those receiving the placebo. More of the patients receiving the drug were able to reduce their prednisone intake, and most reported a better quality of life, although specific numbers were not provided.

About 6% of both patients receiving the drug and those on the placebo suffered side effects, including headache, joint pain and infections.

Experts cautioned that the results have not been peer-reviewed or published in a journal; the significance of this study is unknown at this time. Human Genome Sciences said the results will be published after a second study is completed.

Only three drugs are approved for treating lupus — aspirin, the steroid prednisone and the antimalarial drug Plaquenil (hydroxychloroquine) — and all were approved over 50 years ago during the Eisenhower administration. All can have severe side effects, including stomach bleeding for aspirin; weight gain, bruising, high blood pressure and diabetes for prednisone; and vision problems and muscle weakness for Plaquenil.

Benlysta is a monoclonal antibody known generically as belimumab. It is an immune protein produced artificially, which then binds to and blocks the activity of a protein called B-lymphocyte stimulator. Human Genome Sciences discovered the protein. Elevated levels of B-lymphocyte stimulator are believed to contribute to the production of antibodies that attack the patient’s own organs.

For more information please see: http://www.hgsi.com/belimumab.html

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.